Luly Jay R. 4
4 · ENANTA PHARMACEUTICALS INC · Filed Feb 13, 2026
Research Summary
AI-generated summary of this filing
Enanta (ENTA) CEO Luly Jay Receives 20,000-Share Award; 6,155 Forfeited
What Happened
- Luly Jay R., President, CEO and Director of Enanta Pharmaceuticals (ENTA), received 20,000 shares of common stock on February 12, 2026 from vested equity awards (4,800 PSUs and 15,200 rTSRUs) issued at $0.00. To cover withholding taxes on the settlement, 6,155 shares were automatically forfeited at $14.25 per share, valued at $87,709. Net shares received by the insider from this settlement: 13,845.
Key Details
- Transaction dates: awards vested and shares issued on 2026-02-12; filing submitted 2026-02-13 (timely).
- Transaction types: A = award/grant (4,800 and 15,200 shares issued at $0.00); F = shares forfeited to cover tax withholding (6,155 shares disposed at $14.25).
- Value of shares withheld for taxes: 6,155 × $14.25 = $87,709.
- Shares owned after transaction: not specified in the filing.
- Footnotes: PSUs vested based on two-year R&D milestones (calendar 2024–2025); rTSRU vested based on relative total shareholder return versus Nasdaq Biotech Index over two-year periods; forfeiture of 6,155 shares was an automatic tax-withholding action.
Context
- These were performance-based awards that vested and were settled in stock (not an open-market purchase or sale by the insider). The withheld shares are a routine tax-withholding method and are reported as a disposal (F) for reporting purposes, not a cash sale by the insider.
Insider Transaction Report
Form 4
Luly Jay R.
DirectorPresident and CEO
Transactions
- Award
Common Stock
[F1]2026-02-12+4,800→ 862,826 total - Award
Common Stock
[F2]2026-02-12+15,200→ 878,026 total - Tax Payment
Common Stock
[F3]2026-02-12$14.25/sh−6,155$87,709→ 871,871 total
Footnotes (3)
- [F1]Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2024-2025 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2026.
- [F2]Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over the same 60-day calendar periods two years apart. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2026.
- [F3]Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.
Signature
/s/ Matthew Kowalsky as attorney-in-fact|2026-02-13